19Apr
14Apr
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, today announced that it has entered into an exclusive license agreement with GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, to develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan). GQ1010 has shown a highly differentiated preclinical profile, and is anticipated to enter...
04Nov
Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT. Read more >>
08Sep
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer
Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its senior leadership team. Biren Amin, M.S., M.B.A. has joined the company as its Chief Financial and Strategy Officer. Mr. Amin comes to Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO). “We are delighted Biren has joined our leadership team, particularly at this time of significant...
09Aug
Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer
Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer, where she will oversee the advancement and expansion of the Company’s clinical pipeline. “Dr. Khokhar has a proven track record of successfully bringing novel oncology compounds through clinical development to global approval,” said CEO of Pyramid Biosciences,...
08Jul
FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors
The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors. PBI-200, which is an oral, highly potent and selective inhibitor of TRK kinase, was designed by Pyramid Biosciences to overcome a wide range of on-target resistance mutations that have been observed with first-generation TRK inhibitors. “Oncogenic NTRK gene fusions are found in a broad range of cancers. Orphan designation for drugs in development such...
13Apr
Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). Read more >>
11Jan
Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the appointment of Brian Lestini, MD, PhD as Chief Executive Officer. Dr. Lestini joined Pyramid Biosciences in March 2021 as the Chief Medical Officer, overseeing the advancement and expansion of the company’s clinical pipeline of novel targeted medicines. Pyramid Biosciences’ lead program, PBI-200, currently in Phase 1 clinical trials, is an orally-active, CNS penetrant TRK inhibitor targeting a variety...
02Dec
Pyramid Biosciences’ $864 Million Licensing Deal
Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million. The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death. Founded in 2015, Waltham, Mass.-based...
17Nov